GERD 2004: Issues from the past and a consensus for the future

Best Practice and Research: Clinical Gastroenterology

Volumn 18, Issue SUPPL., 2004, Pages 55-66

  Modlin, Irvin ^a   Kidd, Mark ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acid; Esophagitis; Gastroesophageal reflux disease; History; Management; PPI

Indexed keywords

ANTACID AGENT; ANTINEOPLASTIC AGENT; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; MOLECULAR MARKER; PANTOPRAZOLE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR;

ARTICLE; BARRETT ESOPHAGUS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MUCOSA; HEALING; HEARTBURN; HISTORY OF MEDICINE; HUMAN; MALIGNANT TRANSFORMATION; MEDICAL CARE; METAPLASIA; MILK; MORBIDITY; PATHOPHYSIOLOGY; POPULATION RESEARCH; QUESTIONNAIRE; REFLUX ESOPHAGITIS; SIDE EFFECT; SKILL; STANDARDIZATION; STOMACH ACID; SURGICAL APPROACH; SURGICAL MORTALITY; SYMPTOMATOLOGY; TACHYPHYLAXIS; TREATMENT OUTCOME; TREATMENT PLANNING;

BARRETT ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HISTORY, 20TH CENTURY; HUMANS; PROTON PUMPS;

EID: 10644257827     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2004.06.013     Document Type: Article

References (39)

1. I.M. Modlin M. Kidd K. Lye Gastrointestinal Clinics of North America 13 2003 19-55
2. S.F. Moss D. Armstrong R. Arnold et al. GERD 2003 - a consensus on the way ahead Digestion 67 3 2003 111-117
3. A. Winkelstein Peptic esophagitis (a new clinical entity) JAMA 104 1935 906
4. I. Modlin SF. Moss M. Kidd KD. Lye Gastro-esophageal reflux disease - then and now J Clin Gastroenterol 38 2004 390-402
5. I. Modlin G. Sachs Acid Related Diseases 2nd edn 2004 Lippincott New York
6. N.R. Barrett Chronic peptic ulcer of the œsophagus and 'œsophagitis' Br J Surg 38 1950 175-182
7. K. Iijima E. Henry A. Moriya et al. Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction Gastroenterology 122 5 2002 1248-1257
8. V. Stanghellini D. Armstrong H. Mönnikes K.D. Bardhan Systematic review: Do we need a new gastro-esophageal reflux disease questionnaire? Aliment Pharmacol Ther 19 5 2004 463-479
9. A. Damiano K. Handley E. Adler et al. Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: Further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) Dig Dis Sci 47 2002 1530-1537
10. M. Rothman C. Farup W. Stewart L. Helbers J. Zeldis Symptoms associated with gastroesophageal reflux disease: Development of a questionnaire for use in clinical trials Dig Dis Sci 46 2001 1540-1549
11. K.D. Bardhan V. Stanghellini D. Armstrong et al. Evaluation of GERD Symptoms during therapy. Part 1. Development of the new GERD questionnaire ReQuest™ Digestion 69 4 2004 229-237
12. H. Mönnikes K.D. Bardhan V. Stanghellini et al. Evaluation of GERD Symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest™ in erosice GERD Digestion 69 4 2004 238-244
13. Bardhan KD Stanghellini V Armstrong D et al. International validation of ReQuest™ in patients with endoscopic negative gastroesophagel reflux disease. Aliment Pharmacol Ther 2004; in press
14. A. Nasi J.P. Filho B. Zilberstein et al. Gastroesophageal reflux disease: Clinical, endoscopic, and intraluminal esophageal pH monitoring evaluation Dis Esophagus 14 1 2001 41-49
15. K.L. Goh C.S. Chang K.M. Fock Gastro-oesophageal reflux disease in Asia J Gastroenterol Hepatol 15 3 2000 230-238
16. G.D. Eslick R. Fass Noncardiac chest pain: Evaluation and treatment Gastroenterol Clin N Am 32 2 2003 531-552
17. J.J. Ofman G.H. Dorn M.B. Fennerty R. Fass The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease Aliment Pharmacol Ther 16 2002 261-273
18. N.R. Barrett Chronic peptic ulcer of the œsophagus and 'œsophagitis' Br J Surg 38 1950 175-182
19. T.R. DeMeester Clinical biology of the Barrett's metaplasia, dysplasia to carcinoma sequence Surg Oncol 10 3 2001 91-102
20. N. Shaheen Is there a Barrett's iceberg? Gastroenterology 123 2002 636-639
21. N.J. Shaheen M.A. Crosby E.M. Bozymski R.S. Sandler Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119 2000 333-338
22. S.J. Spechler The natural history of dysplasia and cancer in esophagitis and Barrett esophagus J Clin Gastroenterol 36 supplement 5 2003 S26-S28
23. R.C. Fitzgerald I.T. Saeed D. Khoo M.J. Farthing W.R. Burnham Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus Dig Dis Sci 46 9 2001 1892-1898
24. D.O. Castell Aggressive acid control: Minimizing progression of Barrett's esophagus Am J Mgmt Care 7 2001 S15-S18
25. E.M. Bozymski N.J. Shaheen Barrett's esophagus: Acid suppression, but no regression Am J Gastroenterol 92 1997 556-558
26. W. Tam J. Dent Oesophageal disorders: Future developments Best Pract Res Clin Gastroenterol 16 6 2002 811-833
27. N. Chiba C.J. De Gara J.M. Wilkinson R.H. Hunt Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis Gastroenterology 112 6 1997 1798-1810
28. D.A. Peura P. Malfertheiner Chairmen's summary: Dichotomies and directions in acid-related disorders Aliment Pharmacol Ther 19 supplement 1 2004 77-80
29. S.J. Veldhuyzen van Zanten N. Flook N. Chiba et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group CMAJ 162 supplement 12 2000 S3-S23
30. D.O. Castell P.J. Kahrilas J.E. Richter et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis Am J Gastroenterol 97 2002 575-583
31. A. Gillessen W. Beil I.M. Modlin et al. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms J Clin Gastroenterol 38 4 2004 332-340
32. B.R. Yacyshyn A.B.R Thomson The clinical importance of proton pump inhibitor pharmacokinetics Digestion 66 2002 67-78
33. W. Kromer Relative efficacies of gastric proton-pump inhibitors on a milligram basis: Desired and undesired SH reactions. Impact of chirality Scand J Gastroenterol Suppl 234 2001 3-9
34. R.K. Wong D.G. Hanson P.J. Waring G. Shaw ENT manifestations of gastroesophageal reflux Am J Gastroenterol 95 8 2000 S15-S22
35. S.M. Cheer A. Prakash D. Faulds H.M. Lamb Pantoprazole: An update of its pharmacological properties and therapeutic use in the management of acid-related disorders Drugs 63 1 2003 101-132
36. J.E. Richter Novel medical therapies for gastroesophageal reflux disease beyond proton-pump inhibitors Gastroenterol Clin N Am 31 4 2002 S111-S116
37. P.R. Allison Reflux esophagitis, sliding hiatal hernia, and the anatomy of repair Surg Gynecol Obstet 92 1951 419-431
38. S.J. Spechler E. Lee D. Ahnen et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: Follow-up of a randomized controlled trial JAMA 285 18 2001 2331-2338
39. N. Vakil M. Shaw R. Kirby Clinical effectiveness of laparoscopic fundoplication in a U.S. community Am J Med 114 2003 1-5